Abvc Biopharma (ABVC) Equity Income (2018 - 2021)
Abvc Biopharma's (ABVC) quarterly Equity Income came in at -$76697.0 in Q4 2021, up 24.39% YoY from -$61659.5 in Q4 2020, and up 16.42% on a QoQ basis from -$91765.0 in Q3 2021.
Abvc Biopharma (ABVC) Equity Income (2018 - 2021) Analysis & Trends
Abvc Biopharma (ABVC) has 4 years of Equity Income data on file, last reported at -$76697.0 in Q4 2021.
- Quarterly Equity Income rose 24.39% year-over-year to -$76697.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$269844.0 (up 76.91% YoY) and the FY2023 annual result came in at -$221888.0, changed N/A from the prior year.
- Equity Income rose to -$76697.0 in Q4 2021, from -$91765.0 in the prior quarter.
- In the past five years, Equity Income ranged from a high of -$27973.0 in Q4 2019 to a low of -$887231.0 in Q3 2020.
- A 4-year average of -$115104.7 and a median of -$65447.0 in 2019 frame the typical range for Equity Income.
- Annual changes were most pronounced in 2020 — Equity Income tumbled 1271.53% — and 2021, when it jumped 89.66%.
- Tracing ABVC's Equity Income over 4 years: stood at -$28363.0 in 2018, then increased by 1.38% to -$27973.0 in 2019, then plunged by 262.62% to -$101435.0 in 2020, then climbed by 24.39% to -$76697.0 in 2021.
- The last three Equity Income figures came in at -$76697.0 (Q4 2021), -$91765.0 (Q3 2021), and -$53591.0 (Q2 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.08 Mn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | -76,697.00 |
| Sep 30, 2021 | -91,765.00 |
| Jun 30, 2021 | -53,591.00 |
| Mar 31, 2021 | -47,791.00 |
| Dec 31, 2020 | -101,435.00 |
| Sep 30, 2020 | -887,231.00 |
| Jun 30, 2020 | -109,656.00 |
| Mar 31, 2020 | -70,411.00 |
| Dec 31, 2019 | -27,973.00 |
| Sep 30, 2019 | -64,689.00 |
| Jun 30, 2019 | -51,219.00 |
| Mar 31, 2019 | -66,205.00 |
| Dec 31, 2018 | -28,363.00 |
| Sep 30, 2018 | -39,166.00 |
| Jun 30, 2018 | -86,916.00 |
| Mar 31, 2018 | -38,567.00 |